Adherence to HIV combination therapy
Section snippets
Background to adherence or compliance: A social and behavioural science perspective
Biomedical scientists involved in clinical trial research and health care providers charged with treating persons living with HIV are turning to social and behavioural scientists for assistance with adherence. In particular, there is interest in understanding the factors that account for patients’ difficulties in adhering to care. While some social and behavioural scientists have become very involved in developing measures of adherence, studying explanatory factors and developing programs to
Adherence and emergence of drug resistant virus
All recently published treatment guidelines (Carpenter et al., 1997, Dormont, 1997, Dormont, 1998) have a twofold orientation: positive recommendations and warnings. On the positive side, they confirm the prognostic value of viral load and CD4+ level. The guidelines clearly indicate that one criterion and operational objective for evaluating drug effectiveness is the lowering of viral load, optimally to below a detectable level. The other goal is to rebuild the immune system, which is
The challenge of non-adherence
The new focus on adherence begs two questions. First, what are the levels of adherence that have been seen? Second, how much adherence is necessary to prevent treatment failure? Even the most casual awareness of the factors associated with non-adherence to other conditions should have sent out an alert as the full extent of the medications involved in combination therapy became apparent. Research on adherence over recent decades, independent of HIV/AIDS indicated that adherence decreased as the
Non-adherence — assessment
Determining the level of non-adherence among patients living with HIV/AIDS is complicated by the general methodological difficulties of adherence assessment. There is no “gold standard” of adherence assessment. Self-reported measures of medication adherence are subject to social desirability and recall bias. Despite these weaknesses, this approach has been shown to give satisfactory concurrent and predictive validity when used in a controlled design and multimethod approach (Brooks et al., 1996
Non-adherence — scope of the problem
The existing surveys of adherence to combination therapy indicate that adherence is likely to be a significant problem. Two such preliminary surveys were reported on at the European Conference. Both of these used a self-report instrument designed specifically to assess the extent and reasons for non-adherence. The first of these was a study conducted at San Francisco General Hospital (Hecht et al., 1998a, Hecht et al., 1998b). AIDS outpatients seen during January and February 1997 were given
Social and behavioural factors in non-adherence
Interest in developing strategies to address non-adherence has led to investigations of its correlates. Sociodemographic factors are among the earliest variables to be examined. As is common throughout the adherence literature, non-adherence to HIV therapy is not consistently associated with demographic characteristics (Eldred et al., 1997, Morin and Moatti, 1996, Singh et al., 1996). For example, male gender seemed in some studies associated with decreased adherence, especially when associated
Intervention
As research to identify factors associated with adherence proceeds, and given the urgency of patients on these medications, there is pressure on social and behavioural scientists to provide assistance in modifying this behaviour. Numerous programs incorporating these ideas were presented at the 12th World AIDS Conference in Geneva. These programs are available for the patient and the team consisting of the clinician, nurse and nurse practitioner, pharmacist, social worker/psychologist, and
References (45)
Compliance with treatment regimens in chronic asymptomatic diseases
Am. J. Med.
(1997)- et al.
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, Type 1: A cross-sectional study in a municipal hospital clinic
Am. J. Med.
(1992) Observance, compliance ou adhésion? enjeux sociaux et mécanismes psychiques
- Baker, R., 1996. Summary sheets on HIV protease inhibitor drugs: Indinavir, ritonavir, saquinavir,...
- et al.
Low adherence in antiRetroviral users at Sao Paulo, Brazil
- et al.
A cohort study of drug users’ compliance with zidovudine treatment
Archs Intern Med.
(1994) - et al.
Assessing adherence to asthma medication and inhaler regimens: a psychometric analysis of adult self-report scales
Medical Care
(1996) - et al.
Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society — USA panel
JAMA
(1997) Les implications des essais ACTG 175 et Delta: Paradoxe
Le Journal du Sida
(1995)- et al.
Adherence to combination therapy in AIDS clinical trials
HIV-1 protease inhibitors. A review for clinicians
JAMA
Clinical assessment and management of adherence to medical regimens
Adherence to antiretroviral therapy in HIV disease
Understanding and improving patient compliance
Annals of Internal Medicine
La compliance des patients en questions
Psychologues et Psychologies
Adherence in hypertension and Coronary Heart Disease
Self-reported adherence to antiretroviral medication (ARV) regimens in a community-based sample of HIV-infected adults
Adherence and asthma
Adherence and effectiveness of protease inhibitors in clinical practice
Cited by (261)
Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
2023, International Journal of PharmaceuticsRace, place, and HIV: The legacies of apartheid and racist policy in South Africa
2022, Social Science and MedicineCitation Excerpt :The cycle continues when upon infection with HIV, the combined stigma of HIV and poverty can be strong enough to dissuade one from pursuing treatment (Tsai et al., 2013). Additionally, depression and stigma can reduce adherence to HIV treatment, which can cause viral loads to rebound and viruses to develop resistance (Collins et al., 2006; Tsai et al., 2013; Chesney et al., 2000). In 2012, an estimated 6.2 out of the 6.4 million South Africans estimated to be living with HIV were Black (Shisana et al., 2014).
Fighting nature with nature: antiviral compounds that target retroviruses
2024, Archives of MicrobiologyChapitre 5 FROM INDIVIDUALS TO SOCIAL: THE NEEDS FOR A GLOBAL ETHICS OVERVIEW IN PHARMACOGENOMICS
2024, Journal International de Bioethique et d'Ethique des SciencesA systematic review on experimental studies about patient adherence to treatment
2024, Pharmacology Research and Perspectives